


AMENDMENTSIN THE CLAIMS

Please amend the claims as follows:

1. (currently amended) A method for increasing the concentration of an HIV protease inhibitor in the brain of a patient, said method comprising administering to an HIV infected patient an amount of a 10,11-methanodibenzosuberane of formula (1):



wherein: A is $-\text{CH}_2\text{CH}_2-$; $-\text{CH}_2\text{CHR}^a\text{CH}_2-$ where R^a is H, OH or lower acyloxy; or $-\text{CH}_2\text{CHR}^b\text{CHR}^c\text{CH}_2-$ where one of R^b or R^c is H, OH, or lower acyloxy, and the other is H;

R¹ is H, F, Cl, or Br;

R² is H, F, Cl, or Br; and

R³ is heteroaryl or phenyl optionally substituted with F, Cl, Br, CF₃, CN, NO₂, or OCHF₂; or a pharmaceutically acceptable salt thereof; and

co-administering to the patient a therapeutically effective amount of the HIV protease inhibitor.

2. (original) The method of claim 1 wherein the patient is a male and the concentration of the HIV protease inhibitor is also increased in the patient's testes.


3. (currently amended) The method of claim 1 wherein the HIV protease inhibitor is selected from the group of nelfinavir, indinavir, saquinavir, ritonavir, and amprenavir.

4. (currently amended) The method of claim 3 wherein the HIV protease inhibitor is nelfinavir.

5. (original) The method of claim 1 wherein R^1 and R^2 are F, A is $-\text{CH}_2\text{CHR}^3\text{CH}_2-$, and R^3 is optionally substituted quinolyl.

6. (original) The method of claim 5 wherein R^3 is OH and R^3 is quinol-5-yl.

7. (original) The method of claim 1 wherein the methanodibenzosuberane of formula (I) is a compound of formula (II):




II.

8. (currently amended) A method of treating a patient having an HIV-1 infection comprising:

administering to the patient a therapeutically effective amount of a an HIV protease inhibitor, and

co-administering to the patient an amount of a compound represented by formula (I):



wherein: A is $-\text{CH}_2\text{CH}_2-$; $-\text{CH}_2\text{CHR}^a\text{CH}_2-$ where R^a is H, OH or lower alkoxy; or $-\text{CH}_2\text{CHR}^b\text{CHR}^c\text{CH}_2-$ where one of R^b or R^c is H, OH, or lower alkoxy, and the other is H;

R^1 is H, F, Cl, or Br;

R^2 is H, F, Cl, or Br; and

R^3 is heteroaryl or phenyl optionally substituted with F, Cl, Br, CF_3 , CN, NO_2 , or OCHF_3 ; or a pharmaceutically acceptable salt thereof;

in an amount sufficient to increase brain levels of the HIV protease inhibitor.

9. (original) The method of claim 8 wherein R^1 and R^2 are F, A is $-\text{CH}_2\text{CHR}^a\text{CH}_2-$, and R^3 is optionally substituted quinolyl.


10. (original) The method of claim 9 wherein R^a is OH and R^3 is quinol-5-yl.

11. (currently amended) The method of claim 8 wherein the amount of the compound of formula (I) is sufficient to increase the brain levels of the HIV protease inhibitor without significantly increasing the concentration of the HIV protease inhibitor in the patient's blood.

12. (currently amended) The method of claim 8, wherein the amount of the compound is also sufficient to increase concentrations of the HIV protease inhibitor in the patient's testes.

13. (original) A pharmaceutical composition comprising an antiviral protease inhibitor:

a 10,11-methanodibenzosuberane of formula (I):



wherein: A is $-\text{CH}_2\text{CH}_2-$; $-\text{CH}_2\text{CHR}^a\text{CH}_2-$ where R^a is H, OH or lower alkoxy; or $-\text{CH}_2\text{CHR}^b\text{CHR}^c\text{CH}_2-$ where one of R^b or R^c is H, OH, or lower alkoxy, and the other is H;

R^1 is H, F, Cl, or Br;

R^2 is H, F, Cl, or Br; and

R^3 is heteroaryl or phenyl optionally substituted with F, Cl, Br, CF_3 , CN, NO_2 , or OCHF_3 ; or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier therefor.

14. (original) The composition of claim 13 wherein the methanodibenzosuberane of formula (I) is present in an amount effective to increase brain levels of the protease inhibitor.

15. (original) The composition of claim 14 wherein the methanodibenzosuberane of formula (I) is present in an amount effective to increase brain levels of the protease inhibitor without significantly increasing plasma levels of the protease inhibitor.

16. (original) The composition of claim 13 wherein the protease inhibitor is selected from the group consisting of nelfinavir, indinavir, saquinavir, zidovudine, or amprenavir.


17. (original) The composition of claim 16 wherein the protease inhibitor is nelfinavir.

18. (original) The composition of claim 13 wherein R^1 and R^2 are F.

19. (original) The composition of claim 13 wherein A is $-\text{CH}_2\text{CH}_2\text{CH}_2-$.

20. (original) The composition of claim 13 wherein R3 is a optionally substituted quinolyl.

21. (original) The composition of claim 13 wherein the 10,11-methanodibenzosuberane is the compound of formula (II):



II.

22. (original) The composition of claim 13 wherein the methanodibenzosuberane comprises about 0.005 to 95% of the composition.

23-36. (cancelled)

37. (new) The composition of claim 13 wherein the antiviral protease inhibitor is an HIV protease inhibitor.